Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(14%)
Results Posted
33%(1 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_3
1
14%
Ph phase_1
1
14%
Ph phase_4
3
43%
Ph phase_2
2
29%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 31 (14.3%)
Phase 43 (42.9%)

Trials by Status

recruiting114%
unknown114%
completed343%
terminated229%

Recent Activity

1 active trials
Showing 5 of 7
recruitingphase_4

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

NCT05735639
terminatedphase_3

Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

NCT03090880
terminatedphase_2

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903
unknownphase_1

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

NCT00293501
completedphase_2

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

NCT00061373
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05735639Phase 4

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Recruiting
NCT03090880Phase 3

Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

Terminated
NCT00981903Phase 2

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

Terminated
NCT00293501Phase 1

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Unknown
NCT00061373Phase 2

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

Completed
NCT00203658Phase 4

Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin

Completed
NCT00203580Phase 4

Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7